Skip to main content

glp 1 drugs

4 articles found

Novo Nordisk Slashes Ozempic and Wegovy Prices by 50%

Novo Nordisk dropped a bombshell on the pharmaceutical industry this week, announcing plans to cut the U.S. list prices of its blockbuster GLP-1 drugs — Wegovy, Ozempic, and Rybelsus — by up to 50% starting January 1, 2027. The new uniform list price of $675 per month, down from current prices ranging between $1,027 and $1,350, marks the most aggressive pricing move yet in the rapidly evolving obesity and diabetes drug market. The announcement sent Novo Nordisk shares tumbling to a fresh 52-week low of $37.65, extending a brutal decline that has erased roughly 75% of the stock's value since its mid-2024 peak. The price cuts arrive at a moment of acute vulnerability for the Danish drugmaker. Just days earlier, Novo reported disappointing results from its REDEFINE 4 trial pitting next-generation drug CagriSema against Eli Lilly's tirzepatide (Zepbound), sending shares down over 16% in a single session. With its market capitalization now sitting at roughly $169 billion — down from north of $600 billion at its zenith — Novo Nordisk is attempting a high-stakes pivot: sacrificing near-term pricing power to defend market share against an increasingly dominant Eli Lilly and a swarm of pharma giants preparing to enter the weight-loss arena. The implications extend far beyond one company's balance sheet. Novo's decision reshapes the economics of a drug category projected to exceed $150 billion in annual sales by the end of the decade, puts immediate pressure on Eli Lilly to respond, and could dramatically expand the patient population with affordable access to GLP-1 therapies. For investors, the question is whether this is a desperate retreat or a calculated long-term play.

Novo NordiskGLP-1 drugsOzempic price cut

Novo Nordisk Slashes Ozempic and Wegovy Prices by Up to 50%

Novo Nordisk dropped a bombshell on Tuesday, announcing it will slash the U.S. list prices of its blockbuster weight-loss and diabetes drugs — Wegovy, Ozempic, and Rybelsus — by up to 50% starting January 1, 2027. All three treatments will carry a new list price of $675 per month, down from approximately $1,350 for Wegovy and $1,027 for the diabetes drugs. The move is specifically designed to relieve the cost burden on insured patients with high-deductible health plans or coinsurance benefit structures. The announcement lands at perhaps the worst possible moment for the Danish pharmaceutical giant. Just one day earlier, shares cratered 16% after Novo's next-generation obesity drug CagriSema failed to demonstrate non-inferiority against Eli Lilly's Zepbound in the pivotal REDEFINE-4 phase III trial. The double blow has sent NVO shares tumbling to $38.58 — a new 52-week low — erasing more than half its market capitalization from last year's peak of $93.80. The stock is now down nearly 59% from its highs, and trading at its lowest P/E ratio in years at just 10.5x earnings. For investors, the twin developments crystallize a question that has been building for months: Is Novo Nordisk ceding the GLP-1 weight-loss throne to Eli Lilly, or is this a generational buying opportunity for one of pharma's most profitable franchises?

Novo NordiskOzempicWegovy

LLY: Eli Lilly's $952 Billion Pharma Empire Delivers 85%

Eli Lilly and Company (NYSE: LLY) has transformed from a traditional pharmaceutical giant into the undisputed leader of the weight loss drug revolution. Trading at $1,009.52, the Indianapolis-based company commands a $952 billion market capitalization — making it the most valuable pharmaceutical company in the world. With full-year 2025 revenue of $65.2 billion and net income of $20.6 billion, Lilly's financial trajectory has been nothing short of extraordinary. The story behind Lilly's meteoric rise centers on two blockbuster GLP-1 receptor agonist drugs: Mounjaro (tirzepatide) for type 2 diabetes and Zepbound for chronic weight management. These medications have generated unprecedented demand, propelling quarterly revenue from $12.7 billion in Q1 2025 to $19.3 billion in Q4 2025 — a 52% sequential acceleration in a single year. The stock sits 11% below its 52-week high of $1,133.95 but has surged 62% from its 52-week low of $623.78, reflecting both the massive opportunity ahead and the premium valuation investors are willing to pay. Beyond weight loss, Lilly continues to expand its pipeline across immunology, oncology, and neuroscience. Recent Phase 3 data showed Omvoh achieving over 90% steroid-free remission in Crohn's disease patients at three years — a landmark result that opens another multi-billion-dollar market. For investors, the central question is whether Lilly's growth trajectory justifies paying nearly 44 times earnings for a pharma stock.

LLY stock analysisEli Lilly stockGLP-1 drugs

Analysis: Novo Nordisk Sues Hims & Hers Over Wegovy Copycats

The most explosive battle in the $100 billion GLP-1 drug market erupted into open warfare this week. Novo Nordisk filed a patent infringement lawsuit against Hims & Hers Health on Monday, seeking to permanently ban the telehealth company from selling compounded versions of its blockbuster weight-loss drug Wegovy. The lawsuit came just two days after Hims launched — and then abruptly pulled — a $49-per-month oral semaglutide pill that undercut Novo's FDA-approved Wegovy pill by roughly $100. The legal salvo, combined with a parallel FDA crackdown on compounded GLP-1 ingredients, has sent Hims & Hers stock into freefall. Shares plunged 16% on Monday and dropped another 5.4% on Tuesday to $18.29, bringing the total decline over the past month to approximately 40%. Hims now trades at $18.29 — a staggering 75% below its 52-week high of $72.98. Novo Nordisk, by contrast, rallied 3.6% on Monday and held steady Tuesday at $49.63, though the Danish giant has its own problems: its stock sits 47% below its own 52-week high of $93.80 amid fierce competition and disappointing 2026 guidance. This is no longer a skirmish over compounding pharmacies. It is a defining legal and regulatory showdown that will determine who controls access to the most lucrative class of drugs in a generation — and at what price 1.5 million Americans currently using compounded GLP-1s will pay for their treatment.

GLP-1 drugsNovo NordiskHims and Hers